AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8345034 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20 267 (10 mg and 30 mg)
Number of subjects: 18
Study 8345034 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20 267 (up to 30 mg)
Number of subjects: 18
Study 8345034 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20 267 (all doses)
Number of subjects: 18
Study 3772617 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed educational materials
Number of subjects: 635
Study 3772617 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiocassette educational materials
Number of subjects: 635
Study 3772617 — intervention group
Group type: EXPERIMENTAL
Intervention: Videocassette educational materials
Number of subjects: 635
Study 3772617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational materials mentioned)
Number of subjects: 635
Study 31568235 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenobam
Number of subjects: 0
Study 31568235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29095743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictogram pillbox with text and pictogram instructions
Number of subjects: 30
Study 29095743 — intervention group
Group type: COMPARATOR
Intervention: Standard pillbox with text instructions
Number of subjects: 30
Study 29095743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictogram pillbox
Number of subjects: 30
Study 27562916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (acute infusion)
Number of subjects: 57
Study 27562916 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide (1.8 mg daily)
Number of subjects: 57
Study 27562916 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg daily)
Number of subjects: 57
Study 27562916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 57
Study 24304033 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine pre‐ and postnatal visits with an International Board Certified Lactation Consultant (IBCLC)
Number of subjects: 67
Study 24304033 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronically prompted guidance from prenatal care providers (EP group)
Number of subjects: 67
Study 24304033 — intervention group
Group type: EXPERIMENTAL
Intervention: EP+LC combined
Number of subjects: 67
Study 24304033 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 67
Study 23186566 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% potassium nitrate
Number of subjects: 149
Study 23186566 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% calcium sodium phosphosilicate with fused silica
Number of subjects: 149
Study 23186566 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 3.85% amine fluoride
Number of subjects: 149
Study 23186566 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 149
Study 20381652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 850
Study 20381652 — intervention group
Group type: COMPARATOR
Intervention: UFH plus protamine
Number of subjects: 850
Study 18558913 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-hour multifaceted educational program facilitated by mental health experts
Number of subjects: 55
Study 18558913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 15503298 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase dissolved in lidocaine
Number of subjects: 12
Study 15503298 — intervention group
Group type: COMPARATOR
Intervention: Asparaginase dissolved in sterile water
Number of subjects: 12
Study 11963457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials
Number of subjects: 0
Study 10356074 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g aleurone cereal
Number of subjects: 16
Study 10356074 — intervention group
Group type: COMPARATOR
Intervention: 100 g wheat bran cereal (low folate control)
Number of subjects: 16
Study 10356074 — intervention group
Group type: COMPARATOR
Intervention: 500 microgram folic acid tablet taken with 100 g wheat bran cereal (high folate control)
Number of subjects: 16
Study 7793586 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 0.25 ml of lignocaine 1% via a 25 gauge needle
Number of subjects: 278
Study 7793586 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a 23 gauge Butterfly
Number of subjects: 278
Study 7793586 — intervention group
Group type: COMPARATOR
Intervention: Insertion of a 21 gauge Butterfly
Number of subjects: 278
Study 7793586 — intervention group
Group type: COMPARATOR
Intervention: Insertion of a 20 gauge Venflon
Number of subjects: 278
Study 1899735 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid enriched TPN (n = 49)
Number of subjects: 101
Study 1899735 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN (n = 52)
Number of subjects: 101
Study 6355460 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of the cervical spine
Number of subjects: 52
Study 31237871 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg oral suspension)
Number of subjects: 4724
Study 31237871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4724
Study 28867538 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention bias modification (n=30)
Number of subjects: 60
Study 28867538 — intervention group
Group type: COMPARATOR
Intervention: Control task (n=30)
Number of subjects: 60
Study 26511807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-Cisplatin followed by Gefitinib maintenance therapy (PC/G)
Number of subjects: 111
Study 26511807 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib monotherapy
Number of subjects: 111
Study 24296746 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus reuteri)
Number of subjects: 113
Study 24296746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 21570139 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration oxygen at 15 L/min via a non-rebreather mask
Number of subjects: 22
Study 21570139 — intervention group
Group type: COMPARATOR
Intervention: Air at 15 L/min via a non-rebreather mask
Number of subjects: 22
Study 19653739 — intervention group
Group type: EXPERIMENTAL
Intervention: Illusory-contour figure as an object mask (created by rotating 4 previewed inducers shaped like Pac-Man)
Number of subjects: 0
Study 19653739 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 17580726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid users
Number of subjects: 0
Study 17580726 — intervention group
Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 0
Study 15177526 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nurse visits every 15 days (Group A)
Number of subjects: 100
Study 15177526 — intervention group
Group type: COMPARATOR
Intervention: Control group with nurse visits every 90 days (Group B)
Number of subjects: 100
Study 15177526 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nurse visits (Group A)
Number of subjects: 100
Study 11277163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea-Bands with acupressure buttons applied to both wrists for 4 days
Number of subjects: 0
Study 11277163 — intervention group
Group type: COMPARATOR
Intervention: Sea-Bands without acupressure buttons applied to both wrists for 4 days
Number of subjects: 0
Study 9850350 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous NaF 75 mg/day with calcium 1500 mg/day for a mean of 41 months
Number of subjects: 66
Study 9850350 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous NaF 50 mg/day with calcium 2000 mg/day for a mean of 15 months (10 with vitamin D, 16 without)
Number of subjects: 66
Study 9850350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical low-dose NaF alternating with vitamin D for a mean of 15 months and total treatment duration of 28 months
Number of subjects: 66
Study 9850350 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 patients who did not receive NaF)
Number of subjects: 66
Study 8033618 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave tissue coagulation (MTC)
Number of subjects: 300
Study 8033618 — intervention group
Group type: COMPARATOR
Intervention: CO2 Laser
Number of subjects: 300
Study 2926699 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic training
Number of subjects: 109
Study 2926699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training
Number of subjects: 109
Study 2926699 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo
Number of subjects: 109
Study 2926699 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 109
Study 4947494 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 400 mg daily for 1 year (second year maintenance) in patients with residual cavitation.
Number of subjects: 0
Study 4947494 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg daily for 6 months (second year maintenance) in patients without residual cavitation.
Number of subjects: 0
Study 31814153 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 148
Study 31814153 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment assignment according to the PTR
Number of subjects: 148
Study 31814153 — intervention group
Group type: COMPARATOR
Intervention: Enhanced-care as usual
Number of subjects: 148
Study 30744686 — intervention group
Group type: EXPERIMENTAL
Intervention: Care delivery interventions
Number of subjects: 9
Study 30744686 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale implementation intervention
Number of subjects: 9
Study 30744686 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site implementation intervention
Number of subjects: 9
Study 30744686 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 9
Study 27758126 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 127
Study 25326090 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 600/100 mg twice daily (n=6)
Number of subjects: 24
Study 25326090 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg once daily (n=17)
Number of subjects: 24
Study 25326090 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 600/100 mg once daily (n=1)
Number of subjects: 24
Study 25326090 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbound darunavir
Number of subjects: 24
Study 25326090 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir cord blood/maternal blood ratio
Number of subjects: 24
Study 25326090 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load close to delivery
Number of subjects: 24
Study 25326090 — intervention group
Group type: EXPERIMENTAL
Intervention: Children tested for HIV
Number of subjects: 24
Study 23688108 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐BiT™ game
Number of subjects: 75
Study 23688108 — intervention group
Group type: COMPARATOR
Intervention: non‐I‐BiT™ game
Number of subjects: 75
Study 23688108 — intervention group
Group type: COMPARATOR
Intervention: I‐BiT™ DVD
Number of subjects: 75
Study 21173171 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) concentrations (ng/mL)
Number of subjects: 493
Study 18543493 — intervention group
Group type: EXPERIMENTAL
Intervention: NB‐UVB combined with Yuyin Recipe (YYR) bathing
Number of subjects: 119
Study 18543493 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB alone
Number of subjects: 119
Study 16510944 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG spectral analysis using a novel multi-resolution decomposition algorithm based on Daubechies wavelet transform
Number of subjects: 227
Study 16510944 — intervention group
Group type: COMPARATOR
Intervention: Age-matched normal elderly subjects
Number of subjects: 227
Study 14529800 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 16
Study 14529800 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 16
Study 14529800 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 16
Study 14529800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11252650 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists (CCAs)
Number of subjects: 0
Study 11252650 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 8653997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 60
Study 8653997 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (2 microg/kg)
Number of subjects: 60
Study 1594707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 3840149 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) to the breast and adjacent lymph node areas
Number of subjects: 118
Study 3840149 — intervention group
Group type: EXPERIMENTAL
Intervention: RT followed by 12 cycles of cyclophosphamide, methotrexate, 5 fluorouracil (CMF) and tamoxifen
Number of subjects: 118
Study 3840149 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of adriamycin and vincristine (AV), alternated with 2 cycles of CMF, then RT, followed by another 4 cycles of AV, alternated with 4 CMF; tamoxifen during the entire treatment period
Number of subjects: 118
Study 29792241 — intervention group
Group type: EXPERIMENTAL
Intervention: digital CBT for insomnia (dCBT-I)
Number of subjects: 358
Study 29792241 — intervention group
Group type: COMPARATOR
Intervention: online sleep education (control)
Number of subjects: 358
Study 30268470 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 monotherapy
Number of subjects: 141
Study 30268470 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin combination therapy
Number of subjects: 141
Study 28174456 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced breathing exercise
Number of subjects: 24
Study 28174456 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercises
Number of subjects: 24
Study 28174456 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 28174456 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 and M2 tests of lumbar spine stabilization
Number of subjects: 24
Study 25178810 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led care
Number of subjects: 999
Study 25178810 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive procedures by midwives
Number of subjects: 999
Study 25178810 — intervention group
Group type: COMPARATOR
Intervention: Overall rate of spontaneous delivery
Number of subjects: 999
Study 22221174 — intervention group
Group type: EXPERIMENTAL
Intervention: Smear layer removal (G1)
Number of subjects: 48
Study 22221174 — intervention group
Group type: COMPARATOR
Intervention: Smear layer nonremoval (G2)
Number of subjects: 48
Study 20148607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P) program
Number of subjects: 12499
Study 20148607 — intervention group
Group type: COMPARATOR
Intervention: Patients not enrolled in the P4P program (Control)
Number of subjects: 12499
Study 17319365 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine‐impregnated cord
Number of subjects: 30
Study 17319365 — intervention group
Group type: COMPARATOR
Intervention: Aluminium chloride‐impregnated cord
Number of subjects: 30
Study 15760536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial hypothermia treatment started within 6 hours (Group A)
Number of subjects: 92
Study 15760536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial hypothermia treatment started in 7-10 hours (Group B)
Number of subjects: 92
Study 15760536 — intervention group
Group type: COMPARATOR
Intervention: Cranial hypothermia treatment started in 11-14 hours (Group C)
Number of subjects: 92
Study 11818757 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% inspired carbon dioxide
Number of subjects: 0
Study 11818757 — intervention group
Group type: COMPARATOR
Intervention: 17% inspired oxygen
Number of subjects: 0
Study 9578193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole in fasted condition
Number of subjects: 12
Study 9578193 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole in fed condition
Number of subjects: 12
Study 7662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol 3% in cream, paste and petrolatum applied for 1 hour
Number of subjects: 20
Study 7662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol 3% in cream, paste and petrolatum
Number of subjects: 20
Study 2651251 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (3 x 50 mg)
Number of subjects: 20
Study 2651251 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (2 x 2 mg)
Number of subjects: 20
Study 2651251 — intervention group
Group type: COMPARATOR
Intervention: Gallopamil
Number of subjects: 20
Study 2651251 — intervention group
Group type: COMPARATOR
Intervention: Molsidomine
Number of subjects: 20
Study 319871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (4 mug/kg)
Number of subjects: 10
Study 319871 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol salbutamol (200 mug)
Number of subjects: 10
Study 319871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31053509 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (measured by MEDAS)
Number of subjects: 5801
Study 30928435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low institutional trust
Number of subjects: 961
Study 30928435 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in misinformation
Number of subjects: 961
Study 29020300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffolds (BRS) with 12 months of dual antiplatelet therapy (DAPT)
Number of subjects: 102735
Study 29020300 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable polymer stents (EES/ZES) with DAPT > 12 months
Number of subjects: 102735
Study 29020300 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable polymer stents (EES/ZES) with DAPT < 12 months
Number of subjects: 102735
Study 29020300 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer stents with 12 months of DAPT
Number of subjects: 102735
Study 29020300 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT > 12 months
Number of subjects: 102735
Study 29020300 — intervention group
Group type: COMPARATOR
Intervention: DAPT < 12 months
Number of subjects: 102735
Study 26046532 — intervention group
Group type: EXPERIMENTAL
Intervention: MGIT960
Number of subjects: 693
Study 26046532 — intervention group
Group type: COMPARATOR
Intervention: Lowenstein‐Jensen (LJ)
Number of subjects: 693
Study 23511682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL of contrast medium (Group A)
Number of subjects: 133
Study 23511682 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of contrast medium (Group B)
Number of subjects: 133
Study 23511682 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of contrast medium (Group C)
Number of subjects: 133
Study 22331686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lauric + myristic acid-rich meal (LM), P/S 0.19
Number of subjects: 20
Study 22331686 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid-rich meal (POL), P/S 0.31
Number of subjects: 20
Study 22331686 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid-rich meal (STE), P/S 0.22
Number of subjects: 20
Study 19112218 — intervention group
Group type: EXPERIMENTAL
Intervention: External jugular vein catheterization
Number of subjects: 68
Study 19112218 — intervention group
Group type: COMPARATOR
Intervention: Other central venous catheterization (internal jugular or subclavian vein)
Number of subjects: 68
Study 19112218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 16720705 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 717
Study 16720705 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 717
Study 15312252 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of isosorbide mononitrate (ISMO)
Number of subjects: 144
Study 15312252 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day of isosorbide mononitrate (ISMO)
Number of subjects: 144
Study 15312252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 10937568 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 20
Study 10937568 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 20
Study 10937568 — intervention group
Group type: EXPERIMENTAL
Intervention: dorzolamide
Number of subjects: 20
Study 9295846 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic electrical stimulation (TES) for 1 year
Number of subjects: 0
Study 9295846 — intervention group
Group type: COMPARATOR
Intervention: No TES (control group)
Number of subjects: 0
Study 8123096 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol b.i.d.
Number of subjects: 38
Study 8123096 — intervention group
Group type: COMPARATOR
Intervention: Dipivefrin b.i.d.
Number of subjects: 38
Study 3470498 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 3470498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30518633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocyte (TIL) therapy with lymphocyte-depleting conditioning regimen followed by systemic high-dose aldesleukin
Number of subjects: 29
Study 30518633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocyte (TIL) therapy
Number of subjects: 29
Study 30585471 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation of abdominal acupoints (CV 13, CV 12, CV 10, ST 21, ST 23, ST 20, SP 16, KI 19) with EA (2 Hz/15 Hz, 1 mA, duration of 30 min) for 5 days.
Number of subjects: 60
Study 30585471 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture stimulation of limb acupoints (LI 4, PC 6, ST 36, ST 37, ST 39, SP 9) with EA (2 Hz/15 Hz, 1 mA, duration of 30 min) for 5 days.
Number of subjects: 60
Study 26747317 — intervention group
Group type: EXPERIMENTAL
Intervention: SDQ mapping algorithm using five SDQ subscales
Number of subjects: 0